MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

Could there be a third big pharma acquisition this week? MSD is rumoured to be in talks to buy Revolution Medicines in a deal that could be worth up to $32 billion. The chatter – first reported by the ...